July 14, 2020 / 4:39 PM / 13 days ago

FACTBOX-Drugmakers rush to develop COVID-19 treatments

 (Updates Gilead, Roche, Regeneron)
    July 29 (Reuters) - Drugmakers around the world are rushing to develop treatments for COVID-19, the fast-spreading respiratory disease caused by the novel coronavirus
that has killed hundreds of thousands. Gilead Sciences Inc's remdesivir is at the forefront of the efforts to treat the disease, after it helped shorten hospital
recovery times in a clinical trial.
    The following is a list of major companies that are developing treatments. For a separate FACTBOX on vaccines under development, click here:
    
       
 Date of     Company                        Progress                                                                                      Development stage  Story link 
 last                                                                                                                                                        
 update                                                                                                                                                      
 July 29     Gilead Sciences Inc            The European Union agreed to buy a limited supply of remdesivir, the only drug authorized in  Late-stage trial.              
                                            the EU so far to treat severe COVID-19 patients. Several other countries, including United                       
                                            States, have also granted emergency clearance to the intravenous treatment.                                      
 June 9      AstraZeneca Plc                Received $23.7 million in funding from a U.S. government agency to advance the development    Starting clinical              
                                            of antibody-based COVID-19 treatments.                                                        studies of two     
                                                                                                                                          antibody           
                                                                                                                                          therapies in the   
                                                                                                                                          next few months.   
 July 7      Regeneron Pharmaceuticals Inc  Has begun tests of its experimental antibody cocktail in humans. The U.S. government signed   Late-stage                     
                                            a $450 million contract for its potential COVID-19 antibody cocktail.                         trials.            
 July 29     Roche Holding AG               The Swiss drugmaker's attempt to retool its rheumatoid arthritis drug Actemra/RoActemra to    Late-stage                     
                                            treat patients hospitalized with severe COVID-19-related pneumonia failed in a late-stage     trials.            
                                            trial. The company is also testing Actemra along with Gilead's remdesivir.                                       
 June 16     Eli Lilly                      Has begun early-stage trials for two of its antibody treatments, and late stage trials of     Early-stage,                   
                                            its arthritis drug Olumiant, which is also being tested along with remdesivir.                late-stage.        
 May 1       AbbVie Inc                     Israel has approved generic version of company's branded HIV drug Kaletra. Company has also   Early-stage                    
                                            initiated trial of cancer drug Imbruvica, which it jointly sells with J&J, in COVID-19        trials.            
                                            patients.                                                                                                        
 May 29      Vir Biotechnology Inc          Partnered with Biogen Inc          and Alnylam Pharmaceuticals Inc          for development   Plans to begin                 
                                            of potential coronavirus treatment.                                                           human trials by                
                                                                                                                                          end of year.       
 July 13     Glenmark Pharmaceuticals Ltd   Received Indian regulatory approval to make and sell favipiravir, a version of Fujifilm       Began a                        
                                            Holdings Corp's          antiviral drug Avigan, for treating mild-to-moderate COVID-19        late-stage trial   
                                            infections.                                                                                   in May. Glenmark   
                                                                                                                                          is separately      
                                                                                                                                          testing a          
                                                                                                                                          combination of     
                                                                                                                                          favipiravir and    
                                                                                                                                          umifenovir,        
                                                                                                                                          another            
                                                                                                                                          anti-viral drug.   
 June 16     Not applicable                 A trial by researchers in the United Kingdom showed the steroid drug dexamethasone, made by   Trial ongoing in               
                                            several generic drugmakers, reduced death rates in hospitalized COVID-19 patients. Germany's  children.          
                                            Fresenius SE           has said it has enough supply of the drug at hand, and it would seek                      
                                            to increase supply to keep up sufficient deliveries.                                                             
    

 (Reporting by Manas Mishra and Trisha Roy in Bengaluru; Editing by Arun Koyyur and Shounak Dasgupta)
  
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below